The reiteration of an Outperform rating by a reputable analyst like Andreas Argyrides from Wedbush is a positive signal for Aquestive Therapeutics. It indicates that the analyst believes the company's stock will outperform the market or its sector in the short term. The maintained price target of $4 also suggests that the analyst sees potential for the stock's price to rise to that level. This could lead to increased investor confidence and potentially a short-term increase in the stock's price.